|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 2 | PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma显示文摘ERK pathway regulated the programmed death ligand-1(PD-L1)expression which was linked to the response of programmed death-1(PD-1)/PD-L1 blockade therapy.So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy.In this study,PD0325901,an oral potent ERK inhibitor,strongly enhanced the efficacy of PD-1 antibody in vitro and in vivo models in non-small cell lung carcinoma(NSCLC)cells.Mechanistically,PD0325901 or shRNA-ERK1/2 significantly downregulated the PD-L1 expression in NSCLC cells and increased the CD3+T cells infiltration and functions in tumor tissue.There was a positive correlation between the p-ERK1/2 expression and PD-L1 expression in patients with NSCLC.And the patients with low p-ERK1/2 expression were observed a high response rate of PD-1/PD-L1 blockage therapy.Our results demonstrate that PD0325901,an ERK inhibitor,can enhance the efficacy of PD-1 blockage against NSCLC in vitro and in vivo models.And the combination of ERK inhibitor such as PD0325901 and PD-1/PD-L1 blockage is a promising regimen and encouraged to be further confirmed in the treatment of patients with NSCLC. | Min Luo Yuhui Xia Fang Wang Hong Zhang Danting Su Chaoyue Su Chuan Yang Shaocong Wu Sainan An Suxia Lin Liwu Fu | 2021 | Acta Pharmaceutica Sinica B2021，11，10： | 1 |
| 3 | Simulating tem- poral and spatial variation of evapotranspiration over the Lushi basin显示文摘 | Mo Xingguo Liu Suxia Lin Zhonghui | 2004 | J Hydrology2004，285，14： | 1 |
| 4 | Regional crop yield,water consumption and water use efficiency and their responses to climate change in the North China Plain显示文摘 | Mo Xingguo Liu Suxia Lin Zhonghui | 2009 | Agriculture Ecosystems and Environment2009，134，： | 1 |
| 5 | Simulating Temporal and Spatial Variation of Evapotranspiration over the Lushi Basin 显示文摘 | Mo Xingguo Liu Suxia Lin Zhonghui | 2004 | Journal of Hydrology2004，285，： | 1 |
| 6 | Regional crop yield, water consumption and water use efficiency and their responses to climate change in the North China Plain显示文摘 | Mo Xingguo Liu Suxia Lin Zhonghui | 2009 | Agriculture Ecosystems & Environment2009，134，12： | 1 |
| 7 | Simulating temporal and spatial variation of evapotranspiration over the Lushi basin显示文摘 | Xingguo Mo Suxia Liu Zhonghui Lin Weimin Zhao | 2003 | Journal of Hydrology2003，，1： | 1 |
| 8 | Simulating temporal and spatial variation of evapotranspiration over the Lushi basin显示文摘 | Mo Xingguo Lin Suxia Lin Zhonghui | 2003 | Journal of Hydrology2003，285，： | 1 |
| 9 | Crop yield responses to climate change in the Huang-Huai-Hai Plain of China显示文摘 | Suxia Liu Xingguo Mo Zhonghui Lin Yueqing Xu Jinjun Ji Gang Wen Jeff Richey | 2010 | Agricultural Water Management2010，，8： | 1 |
| 10 | Effects of surface characteristics of activated carbon on the adsorption of 2-methylisobornel (MIB) and geosmin from natural water 显示文摘 | Jianwei Yu Min Yang Tsair - Fuh Lin Zhaohai Guo Yu Zhang Junnong Gu Suxia Zhang | 2007 | Separation and Purification Technology2007，56，： | 1 |
| 11 | Early growth re-sponse protein-1 promoter-mediated synergistic antitumor effect ofhTERTC27 gene therapy and 5 -Flurorouracil on nasopharyngealcarcinoma显示文摘 | Guimiao Lin Marie Chia-Mi Lin Suxia | 2012 | Cancer biotherapy & radiopharmaceuticals2012，27，7： | 1 |
| 12 | Early growth response protein - 1 promoter - mediated synergistic anti - tumor effect of hTERTC27 gene therapy and 5 - Flu- rorouracil on nasopharyngeal carcinoma显示文摘 | Guimiao Lin Marie Chia - Mi Lin Suxia | 2012 | Cancer biother- apy & radiopharmaceuticals2012，27，7： | 1 |
| 13 | Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma显示文摘Objective:Angioimmunoblastic T cell lymphoma(AITL)is an aggressive form of non-Hodgkin lymphoma derived from mature T cells.However,the underlying pathogenesis of AITL remains unresolved.We aimed to explore the role of FOXO1-mediated signaling in the tumorigenesis and progression of AITL.Methods:FOXO1 expression was assessed using immunohistochemistry on a total of 46 AITL tissue samples.Retroviruses encoding FOXO1 shRNA were used to knockdown FOXO1 expression in CD4^+T cells.Flow cytometric assays analyzed the proliferation and survival of FOXO1 knockdown CD4^+T cells.Furthermore,we performed adoptive T-cell transfer experiments to identify whether inactivation of FOXO1 induced neoplastic follicular-helper T(Tfh)cell polarization and function.Results:Patients with low FOXO1 protein levels were prone to have an advanced tumor stage(P=0.049),higher ECOG ps(P=0.024),the presence of bone marrow invasion(P=0.000),and higher IPI(P=0.035).Additionally,the survival rates of patients in the FOXO1 high-expression group were significantly better than those in the FOXO1 low-expression group(χ^2=5.346,P=0.021).We also observed that inactivation of FOXO1 increased CD4^+T cell proliferation and altered the survival and cell-cycle progression of CD4^+T cells.Finally,we confirmed that inactivation of FOXO1 induces Tfh cell programing and function.Conclusions:Inactivation of FOXO1 in AITL plays a key role in the tumorigenesis and progression of AITL.We propose that FOXO1 expression could be a useful prognostic marker in AITL patients to predict poor survival,and to design appropriate therapeutic strategies. | Meifang Xu Fei Wang Hong Chen Lin Liu Wenwen Liu Yinghong Yang Qiaoling Zheng Lihong Zhang Xiaoxuan Li Suxia Lin Shengbing Zang | 2019 | Cancer Biology & Medicine2019，16，4： | 1 |
| 14 | Simulation temporal and spatial variation of evapotranspiration over Lushi Basin 显示文摘 | MO Xingguo LIU Suxia LIN Zhonghui | 2004 | Journal of Hydrology2004，285，： | 1 |
| 15 | Erratum to Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma显示文摘In the published article1,an error appeared in Acknowledgments on page 753.We omitted Natural Science Foundation of Guangdong Province from Acknowledgments,and we updated it as below.We apologize for the errors and for any confusion it may have caused. | Meifang Xu Fei Wang Hong Chen Lin Liu Wenwen Liu Yinghong Yang Qiaoling Zheng Lihong Zhang Xiaoxuan Li Suxia Lin Shengbing Zang | 2020 | Cancer Biology & Medicine2020，17，1： | 0 |
| 16 | Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma显示文摘Objective:To explore the clinical significance of serum midkine(MDK) levels for the diagnosis of hepatocellular carcinoma(HCC) and evaluate the efficacy of interventional therapy.Methods:Eighty-four patients with HCC were enrolled in this retrospective study.They received an interventional treatment.A follow-up was performed every 2 months,using magnetic resonance imaging,to determine whether the treatment should be continued.Serum alpha-fetoprotein(AFP) and MDK levels were measured at the first diagnosis and during the follow-ups,and the HCC detection rates based on the cutoff values of these two measurements were compared.The relationships between AFP and MDK and the clinical tumor characteristics and changes in APK and MDK before and after treatment were also compared using a rank sum test and χ2 test,respectively.The prognostic significance of MDK for HCC was determined through regression analysis.A twosided P <0.05 was considered statistically significant.Results:MDK expression was detected in 95.24% of the cases.Subgroup analysis revealed MDK expression in95.35%,95.12%,85.19%,86.67%,and 83.33% of the AFP-positive,AFP-negative,stage A Barcelona clinic liver cancer(BCLC-A),BCLC-A/AFP-positive,and BCLC-A/AFP-negative cases,respectively.MDK expression after the interventional treatment(66.7%) was significantly lower than that before the treatment(95.2%).The mean posttreatment MDK level was 0.67 ng/mL in patients with a positive response to therapy as compared with 3.66 ng/mL in those with no positive response.All patients were followed up for 18 months,and those positive for MDK expression before the intervention were more likely to relapse than patients without MDK expression.Subgroup analysis revealed the highest recurrence rate for patients who were positive for MDK expression before and after treatment.Conclusions:Serum MDK may serve as a powerful complement to AFP in the diagnosis of HCC.MDK measurement may improve the detection rate of BCLC-A and AFP-negative HCC.Serum MDK may help to determine the vascular invasion and poor clinical staging of HCC tumors.Patients with MDK-positive HCC before treatment may be more prone to postoperative tumor progression. | Lin Zheng Hailiang Li Jinhua Huang Jihoon Shin Suxia Luo Chenyang Guo Yan Zhao Fangkun Li | 2021 | Journal of Interventional Medicine2021，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员